Harrow Inc (HROW)

$31.00 +0.34 (1.11%)
Market Cap 1.12B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 183.96
Profit Margin -8.76%
Debt to Equity Ratio 2.01
Volume 343,200
Avg Vol 443,382
Day's Range N/A - N/A
Shares Out 36.69M
Stochastic %K 28%
Beta 0.40
Analysts Strong Sell
Price Target $58.03

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
Finnish_boy
Finnish_boy Jun. 23 at 11:20 PM
$HROW Indexes heading new ATH.. my HROW pt $35 in June possible but markets need to wake up really, really fast.. but $40 in July very likely imo. In August we should see over $50 levels after Q2 report.
1 · Reply
ACNY555
ACNY555 Jun. 23 at 2:02 PM
$HROW you would have thought Harrow's facility was the one bombed the way its been trading lately.
0 · Reply
Fullback
Fullback Jun. 23 at 1:37 PM
$HROW hmmmmm sub $30.
1 · Reply
Power2numbers
Power2numbers Jun. 22 at 1:12 AM
$HROW Looks like Monday will be a great day to add more shares with tonight's news.
0 · Reply
Tennis_4567
Tennis_4567 Jun. 20 at 6:35 PM
$HROW here we go again
1 · Reply
HROW200
HROW200 Jun. 19 at 2:52 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 9:59 PM
$HROW https://www.optometricmanagement.com/issues/2025/june/industry-insights-mark-l-baum-founder-and-chief-executive-officer-harrow/
1 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 8:30 PM
$HROW Vevye with its access program will be #1 topic in H2.. huge RXs numbers already knocking door "We are also looking to add partner pharmacies to this program, so stay tuned."
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 5:47 PM
$HROW VEVYE skyrocket and IHEEZO and TRIESENCE grow steadily.. slower ramp up but peak revenue high at the end. Lack of coverage slows down but TAM is very big anyways. https://ophthalmologymanagement.com/issues/2025/june/industry-insider/?fbclid=IwY2xjawK_ybRleHRuA2FlbQIxMQABHvJOp3RsxmNzrHgrIEsJDda3GhZYSYP7HMToPazqQ472aPRF3Ax9Sp4GZHew_aem_jt_XceCpSOx3EX5vXydH4Q
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 4:43 PM
$HROW Both Iheezo and Triesence great products, they need time bc lack of coverage. Buckle up!
0 · Reply
Latest News on HROW
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 18, 2025, 7:00 AM EDT - 5 days ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 10 days ago

I Am Swimming In Dividends With +7% Yields

UMH

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Jun 9, 2025, 7:00 AM EDT - 14 days ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 26 days ago

Harrow: Epic Growth & Operating Leverage On Full Display

Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 5 weeks ago

Harrow to Present at Two Investor Conferences in May

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 6 weeks ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 6 weeks ago

Harrow Announces First-Quarter 2025 Financial Results

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

May 5, 2025, 7:00 AM EDT - 7 weeks ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 2 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Apr 10, 2025, 7:00 AM EDT - 2 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 3 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 3 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 28, 2025, 1:39 PM EDT - 3 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 4:01 PM EDT - 3 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 27, 2025, 10:45 AM EDT - 3 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 24, 2025, 7:00 AM EDT - 3 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 4:01 PM EDT - 3 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Harrow Launches VEVYE® Access for All

Mar 17, 2025, 7:00 AM EDT - 3 months ago

Harrow Launches VEVYE® Access for All

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 11, 2025, 7:00 AM EDT - 3 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 3, 2025, 7:15 AM EST - 4 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Mar 1, 2025, 8:50 AM EST - 4 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

I Am Loading Up Big Dividends For My Golden Years

Feb 17, 2025, 7:35 AM EST - 4 months ago

I Am Loading Up Big Dividends For My Golden Years

HQH

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

Jan 27, 2025, 7:30 AM EST - 5 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Jan 7, 2025, 7:00 AM EST - 5 months ago

Harrow Appoints Amir H. Shojaei as Chief Scientific Officer

Those Derisked Baby Bonds Of Harrow, Inc.

Jan 3, 2025, 3:43 PM EST - 6 months ago

Those Derisked Baby Bonds Of Harrow, Inc.

Harrow: The Triesence Relaunch

Dec 14, 2024, 12:09 AM EST - 6 months ago

Harrow: The Triesence Relaunch

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Nov 21, 2024, 7:00 AM EST - 7 months ago

Harrow's ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

Harrow Announces Participation in Upcoming Investor Conferences

Nov 15, 2024, 7:00 AM EST - 7 months ago

Harrow Announces Participation in Upcoming Investor Conferences

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 2:56 PM EST - 7 months ago

Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript

Harrow Announces Third Quarter 2024 Financial Results

Nov 13, 2024, 4:34 PM EST - 7 months ago

Harrow Announces Third Quarter 2024 Financial Results

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Nov 13, 2024, 7:00 AM EST - 7 months ago

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

GDRX

Harrow Announces Market Access Wins for VEVYE®

Nov 12, 2024, 7:00 AM EST - 7 months ago

Harrow Announces Market Access Wins for VEVYE®

Harrow: VEVYE And Its Impact On The DED Market

Nov 11, 2024, 6:37 AM EST - 8 months ago

Harrow: VEVYE And Its Impact On The DED Market

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Nov 7, 2024, 7:00 AM EST - 8 months ago

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow's Branded Eyecare Products

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Oct 31, 2024, 7:00 AM EDT - 8 months ago

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

I Am Banking On The Silver Tsunami With Big Dividends

Oct 12, 2024, 10:30 AM EDT - 9 months ago

I Am Banking On The Silver Tsunami With Big Dividends

THQ XOMA

Harrow Relaunches TRIESENCE®

Oct 3, 2024, 7:00 AM EDT - 9 months ago

Harrow Relaunches TRIESENCE®

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Oct 2, 2024, 12:10 PM EDT - 9 months ago

Harrow Inc (HROW) Shares Up 3.26% on Oct 2

Harrow Announces Nashville Expansion

Sep 25, 2024, 12:02 PM EDT - 9 months ago

Harrow Announces Nashville Expansion

Harrow to Present at Three Investor Conferences in September in New York

Sep 3, 2024, 7:00 AM EDT - 10 months ago

Harrow to Present at Three Investor Conferences in September in New York

Harrow: Bulls On Parade

Aug 16, 2024, 3:42 PM EDT - 11 months ago

Harrow: Bulls On Parade

Harrow Announces Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 11 months ago

Harrow Announces Second Quarter 2024 Financial Results

Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks

Aug 1, 2024, 3:29 AM EDT - 11 months ago

Don't Buy AI Stocks, Buy The Best Dividend Total Return Stocks

ARLP BEPC BMY BTI BXSL DOW EG

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Jul 25, 2024, 7:00 AM EDT - 11 months ago

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Harrow to Attend 2024 ASRS Annual Meeting

Jul 12, 2024, 7:00 AM EDT - 1 year ago

Harrow to Attend 2024 ASRS Annual Meeting

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Top 3 Health Care Stocks That May Crash This Quarter

Jul 3, 2024, 9:41 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash This Quarter

LBPH LLY

Harrow Successfully Manufactures Triesence; Management Credibility Soars

Jun 24, 2024, 11:42 AM EDT - 1 year ago

Harrow Successfully Manufactures Triesence; Management Credibility Soars

Harrow Provides TRIESENCE® Relaunch Update

Jun 20, 2024, 7:00 AM EDT - 1 year ago

Harrow Provides TRIESENCE® Relaunch Update

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Finnish_boy
Finnish_boy Jun. 23 at 11:20 PM
$HROW Indexes heading new ATH.. my HROW pt $35 in June possible but markets need to wake up really, really fast.. but $40 in July very likely imo. In August we should see over $50 levels after Q2 report.
1 · Reply
ACNY555
ACNY555 Jun. 23 at 2:02 PM
$HROW you would have thought Harrow's facility was the one bombed the way its been trading lately.
0 · Reply
Fullback
Fullback Jun. 23 at 1:37 PM
$HROW hmmmmm sub $30.
1 · Reply
Power2numbers
Power2numbers Jun. 22 at 1:12 AM
$HROW Looks like Monday will be a great day to add more shares with tonight's news.
0 · Reply
Tennis_4567
Tennis_4567 Jun. 20 at 6:35 PM
$HROW here we go again
1 · Reply
HROW200
HROW200 Jun. 19 at 2:52 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 9:59 PM
$HROW https://www.optometricmanagement.com/issues/2025/june/industry-insights-mark-l-baum-founder-and-chief-executive-officer-harrow/
1 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 8:30 PM
$HROW Vevye with its access program will be #1 topic in H2.. huge RXs numbers already knocking door "We are also looking to add partner pharmacies to this program, so stay tuned."
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 5:47 PM
$HROW VEVYE skyrocket and IHEEZO and TRIESENCE grow steadily.. slower ramp up but peak revenue high at the end. Lack of coverage slows down but TAM is very big anyways. https://ophthalmologymanagement.com/issues/2025/june/industry-insider/?fbclid=IwY2xjawK_ybRleHRuA2FlbQIxMQABHvJOp3RsxmNzrHgrIEsJDda3GhZYSYP7HMToPazqQ472aPRF3Ax9Sp4GZHew_aem_jt_XceCpSOx3EX5vXydH4Q
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 4:43 PM
$HROW Both Iheezo and Triesence great products, they need time bc lack of coverage. Buckle up!
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 4:39 PM
$HROW "The program, which is available through Harrow’s PhilRx specialty pharmacy partner, guarantees access to Vevye for eligible patients and health plans for $59. The program also provides free home delivery and allows patients to choose to use their insurance coverage or to take advantage of Harrow’s cash price."
0 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 11:27 AM
$HROW
1 · Reply
Finnish_boy
Finnish_boy Jun. 18 at 11:19 AM
$HROW https://investors.harrow.com/news-releases/news-release-details/harrow-appoints-mike-biega-vice-president-investor-relations-and/
1 · Reply
Finnish_boy
Finnish_boy Jun. 17 at 10:28 PM
$HROW I would suggest the next incentive at $100 and the next one at $200.
1 · Reply
Tennis_4567
Tennis_4567 Jun. 17 at 7:37 PM
$HROW are we seriously looking at sub $30 again?
2 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 11:15 PM
$HROW My porfolio is going to explode in a year. HROW Vevye skyrockets. IREN first data center deal in Q3-Q4, HITI medical cannabis entry in Q3, and GOSS positive readout in February. GLNG is also familiar to me and easy money in long-term but i dont hold it atm bc my other stocks better R/R atm.
1 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 9:54 PM
$HROW Q2: VEVYE >=25M IHEEZO>=15M IMPRIMISRX + TRIESENCE + OTHER =25M Total >65m.. i expect 67-70m.. and very bullish outlook. SP over $50 after the Q2 report. Easy money🤑
2 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 9:23 PM
$HROW I am 100% sure that Harrow acquires MELT-300 in a year.. most likely in H2 25. It's such a no-brainer deal for Harrow as Baum and Boll have told many times. Upfront+ milestone and roaylties. Whole Melt is worth about 200m so Harrow can buy MELT-300. They can sell rest of world rights and other than ophthalmic use of cases in US. Not sure about exact terms but they will buy MELT-300. Replacing MKO melt + growth + roaylties = big revenue.. Also, i expect some other acquisition in a year🚀
0 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 2:37 PM
$HROW Aggressive marketing ("bypass insurance" -option, more RXs with lower ASP) + much better product (look at comparison) = Harrow can disrupt a lot and gain nice market share. And this product enhances further the foundation for future acquisitions.
1 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 12:41 PM
$HROW
0 · Reply
Finnish_boy
Finnish_boy Jun. 16 at 12:39 PM
$HROW Is the next acquisition MELT-300 in Q3-Q4. I think so. Lets see. This one was amazing. Glad Formosa picked Harrow. Harrow is already enough attractive. Apotex sells that in Canada.
1 · Reply
Finnish_boy
Finnish_boy Jun. 15 at 10:21 PM
$HROW
0 · Reply